title: Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity.
abstract: OBJECTIVE
  The aim of this study was to evaluate the feasibility and toxicity of concurrent chemoradiotherapy (CCRT) with S-1 in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) in elderly cases and/or cases with comorbidity.
  
  
  METHODS
  Fifty eligible patients with stage III (15 cases) or stage IV (35 cases) SCCHN were treated with CCRT. Thirteen cases had an advanced age of over 75 years and 37 cases had comorbidity. Definitive radiotherapy was delivered up to a total dose of 66-70.2 Gy. The patients received two courses of oral S-1 (40 or 50 mg twice a day [80 or 100 mg/day]) for 2 weeks followed by 1 week of rest while receiving CCRT.
  
  
  RESULTS
  All the patients received the planned radiotherapy and at least one course of S-1. Grade 3 mucositis occurred in 20% of the patients (10/50). Grade 3 neutropenia occurred in 12% (6/50) and leukocytopenia occurred in 6% (3/50) of the cases. Pathologically, the complete response rates were 93% in stage III and 54% in stage IV.
  
  
  CONCLUSIONS
  Concurrent chemoradiotherapy with S-1 is a safe, well-tolerated and effective regimen for locally advanced SCCHN in elderly cases and/or cases with comorbidity.
authors.affiliation: Department of Otorhinolaryngology, and Head and Neck Surgery, Yokohama City University School of Medicine, Yokohama, Japan. mtsukuda@med.yokohama-cu.ac.jp
authors.forename: Mamoru
authors.initials: M
authors.lastname: Tsukuda
authors.forename: Junichi
authors.initials: J
authors.lastname: Ishitoya
authors.forename: Yasukazu
authors.initials: Y
authors.lastname: Mikami
authors.forename: Hideki
authors.initials: H
authors.lastname: Matsuda
authors.forename: Choichi
authors.initials: C
authors.lastname: Horiuchi
authors.forename: Takahide
authors.initials: T
authors.lastname: Taguchi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Satake
authors.forename: Toshiro
authors.initials: T
authors.lastname: Kawano
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takahashi
authors.forename: Goshi
authors.initials: G
authors.lastname: Nishimura
authors.forename: Mariko
authors.initials: M
authors.lastname: Kawakami
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Sakuma
authors.forename: Makiko
authors.initials: M
authors.lastname: Watanabe
authors.forename: Osamu
authors.initials: O
authors.lastname: Shiono
authors.forename: Masanori
authors.initials: M
authors.lastname: Komatsu
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Yamashita
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D006258:Head and Neck Neoplasms / Q000150:complications / Q000601:surgery / Q000628:therapy*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid